Literature DB >> 3015404

Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.

B S Kramer, R Birch, J P Gockerman, A Greco, K Prestridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3015404

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

Authors:  P B Jensen; S K Larsen; I Stilbo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Authors:  P B Jensen; L Vindeløv; H Roed; E J Demant; M Sehested; T Skovsgaard; H H Hansen
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.